In Q2 2026, RTW Investments held 81 positions worth $11.6B. They initiated 5 new positions and exited 76. Their largest holding was MDGL ($1.1B). Portfolio value grew +13.9% versus the prior quarter.
Frequently asked questions
What stocks did RTW Investments own in Q2 2026?
RTW Investments held 81 biotech stocks in their 13F portfolio in Q2 2026. Their top positions include MDGL, ARGX, PTCT, PTGX, CGON. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was RTW Investments's portfolio worth in Q2 2026?
RTW Investments's tracked biotech portfolio was worth $11.6B across 81 positions, with total assets under management of approximately $10B. Portfolio values are based on 13F filings with the SEC.
What did RTW Investments buy in Q2 2026?
RTW Investments initiated 5 new positions in Q2 2026, including KLRA, AXGN, SLDB, ALLO, MAZE. They also increased 28 existing positions.
What did RTW Investments sell in Q2 2026?
RTW Investments fully exited 76 positions in Q2 2026, including MLTX, SAGE, VCEL, CNTA, ARWR and 71 more. They also trimmed 9 existing positions.
Is RTW Investments a biotech fund?
Data-driven biotech fund led by a physician-investor who combines clinical expertise with quantitative analysis. RTW takes concentrated positions across the biotech lifecycle, from crossover privates to public equities, with a focus on therapeutic areas where clinical data can be independently modeled.
Want AI analysis, insider signals, and catalyst overlays for RTW Investments?
View latest RTW Investmentsportfolio →